Overview
CVKD market data
Price History
CVKD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.64 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.78 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.77 – $14.64 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.6M · P/B 5.79.
Company News
Cadrenal Therapeutics Q2 EPS $(1.14) Beats $(1.42) EstimateBenzinga · Aug 13, 2026, 8:46 PM
Cadrenal Therapeutics Consolidates Multi-Indication Strategy For Cardiac Acute Critical Care Franchise, With Focus On CAD-1005 For Both HIT And CSA-AKIBenzinga · Aug 3, 2026, 12:31 PM
8-K filing — Cadrenal Therapeutics, Inc. (CVKD)SEC EDGAR · Jul 21, 2026, 12:30 PM
Cadrenal Therapeutics Unveils Cardiac Critical Care Franchise, Seeks Partners For Late-Stage Cardiovascular AssetsBenzinga · Jul 21, 2026, 12:24 PM
Cadrenal Therapeutics Launches Partnering ProcessBenzinga · Jul 21, 2026, 12:03 PM
Cadrenal Therapeutics shares are trading lower after CAD‑1005 Phase 2 data signaled efficacy but lacked statistical power.Benzinga · Jul 13, 2026, 5:46 PM
Cadrenal Therapeutics’ Late-Breaking Clinical Data From Phase 2 Study Of 12-LOX Inhibitor CAD-1005 Featured In Oral Presentation At ISTH 2026 CongressBenzinga · Jul 13, 2026, 1:02 PM
Cadrenal Therapeutics Appoints John P. Sharp As Interim CFO Effective June 25, 2026; Quang X. Pham Ceases To Serve As Interim CFOBenzinga · Jun 29, 2026, 9:30 PM
Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accepted For Oral Presentation At 34th Congress Of ISTHBenzinga · Jun 24, 2026, 12:10 PM
Cadrenal Therapeutics Plans To Submit An FDA Rare Pediatric Disease Designation Request For Tecarfarin As A Treatment For Pediatric Patients With Kawasaki Disease And Coronary Artery Aneurysms Who Need Chronic Oral AnticoagulationBenzinga · Jun 18, 2026, 1:10 PM